| Stanley Szwed, MD | |
|
925 Clifton Ave, Suite# 108, Clifton, NJ 07013-2724 | |
| (973) 471-6200 | |
| (973) 471-6221 |
| Full Name | Stanley Szwed |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 42 Years |
| Location | 925 Clifton Ave, Clifton, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1629023478 | NPI | - | NPPES |
| 1834509 | Medicaid | NJ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | MA473740 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Mary's General Hospital | Passaic, NJ | Hospital |
| St Joseph's Hospital And Medical Center | Paterson, NJ | Hospital |
| Saint Clare's Hospital/ Denville Campus | Denville, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ghcp Ekg Interpretation Panel, Llc | 1153374673 | 3 |
| St Marys General Medical Group Pc | 5496112476 | 15 |
| Smgh Physician Practice Management Llc | 6406141480 | 3 |
News Archive
Sapheon Inc. has completed the first closing in its $18.5 million Series B Preferred equity offering. The Company issued 4,775,291 shares worth $8.6 million to Series B purchasers and convertible notes holders.
Celsis International, the global leader in rapid microbial detection, announced it has recently updated its Drug Master Files with the U.S. Food & Drug Administration (FDA) to include information on testing both non-sterile and sterile raw materials, in-process solutions and finished goods on the Celsis system.
Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced the U.S. Food and Drug Administration (FDA) has agreed to the Company's updated product specifications for SURFAXIN® (lucinactant) Intratracheal Suspension which was approved for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk for RDS.
The Wilson Medical Center Board of Directors has taken the next step in becoming part of Duke LifePoint Healthcare. The organizations have signed a definitive agreement to form a joint venture. The proposed joint venture, which will provide Wilson Medical Center with resources to enhance its services and invest in its growth, is moving forward following a positive vote by the Wilson County Board of Commissioners. The agreement is under review by the Attorney General of North Carolina.
For years, pharmaceutical companies have sought to restrict public access to drug safety data collected in clinical trials on the basis that it is proprietary information, arguing that competitors could use that information in the development of their own products.
› Verified 1 days ago
| Entity Name | Ghcp Ekg Interpretation Panel, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669697009 PECOS PAC ID: 1153374673 Enrollment ID: O20050224000708 |
News Archive
Sapheon Inc. has completed the first closing in its $18.5 million Series B Preferred equity offering. The Company issued 4,775,291 shares worth $8.6 million to Series B purchasers and convertible notes holders.
Celsis International, the global leader in rapid microbial detection, announced it has recently updated its Drug Master Files with the U.S. Food & Drug Administration (FDA) to include information on testing both non-sterile and sterile raw materials, in-process solutions and finished goods on the Celsis system.
Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced the U.S. Food and Drug Administration (FDA) has agreed to the Company's updated product specifications for SURFAXIN® (lucinactant) Intratracheal Suspension which was approved for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk for RDS.
The Wilson Medical Center Board of Directors has taken the next step in becoming part of Duke LifePoint Healthcare. The organizations have signed a definitive agreement to form a joint venture. The proposed joint venture, which will provide Wilson Medical Center with resources to enhance its services and invest in its growth, is moving forward following a positive vote by the Wilson County Board of Commissioners. The agreement is under review by the Attorney General of North Carolina.
For years, pharmaceutical companies have sought to restrict public access to drug safety data collected in clinical trials on the basis that it is proprietary information, arguing that competitors could use that information in the development of their own products.
› Verified 1 days ago
| Entity Name | Smgh Physician Practice Management Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033578075 PECOS PAC ID: 6406141480 Enrollment ID: O20160830001733 |
News Archive
Sapheon Inc. has completed the first closing in its $18.5 million Series B Preferred equity offering. The Company issued 4,775,291 shares worth $8.6 million to Series B purchasers and convertible notes holders.
Celsis International, the global leader in rapid microbial detection, announced it has recently updated its Drug Master Files with the U.S. Food & Drug Administration (FDA) to include information on testing both non-sterile and sterile raw materials, in-process solutions and finished goods on the Celsis system.
Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced the U.S. Food and Drug Administration (FDA) has agreed to the Company's updated product specifications for SURFAXIN® (lucinactant) Intratracheal Suspension which was approved for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk for RDS.
The Wilson Medical Center Board of Directors has taken the next step in becoming part of Duke LifePoint Healthcare. The organizations have signed a definitive agreement to form a joint venture. The proposed joint venture, which will provide Wilson Medical Center with resources to enhance its services and invest in its growth, is moving forward following a positive vote by the Wilson County Board of Commissioners. The agreement is under review by the Attorney General of North Carolina.
For years, pharmaceutical companies have sought to restrict public access to drug safety data collected in clinical trials on the basis that it is proprietary information, arguing that competitors could use that information in the development of their own products.
› Verified 1 days ago
| Entity Name | St Marys General Medical Group Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477261741 PECOS PAC ID: 5496112476 Enrollment ID: O20230607000110 |
News Archive
Sapheon Inc. has completed the first closing in its $18.5 million Series B Preferred equity offering. The Company issued 4,775,291 shares worth $8.6 million to Series B purchasers and convertible notes holders.
Celsis International, the global leader in rapid microbial detection, announced it has recently updated its Drug Master Files with the U.S. Food & Drug Administration (FDA) to include information on testing both non-sterile and sterile raw materials, in-process solutions and finished goods on the Celsis system.
Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced the U.S. Food and Drug Administration (FDA) has agreed to the Company's updated product specifications for SURFAXIN® (lucinactant) Intratracheal Suspension which was approved for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk for RDS.
The Wilson Medical Center Board of Directors has taken the next step in becoming part of Duke LifePoint Healthcare. The organizations have signed a definitive agreement to form a joint venture. The proposed joint venture, which will provide Wilson Medical Center with resources to enhance its services and invest in its growth, is moving forward following a positive vote by the Wilson County Board of Commissioners. The agreement is under review by the Attorney General of North Carolina.
For years, pharmaceutical companies have sought to restrict public access to drug safety data collected in clinical trials on the basis that it is proprietary information, arguing that competitors could use that information in the development of their own products.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Stanley Szwed, MD 925 Clifton Ave, Suite# 108, Clifton, NJ 07013-2724 Ph: (973) 471-6200 | Stanley Szwed, MD 925 Clifton Ave, Suite# 108, Clifton, NJ 07013-2724 Ph: (973) 471-6200 |
News Archive
Sapheon Inc. has completed the first closing in its $18.5 million Series B Preferred equity offering. The Company issued 4,775,291 shares worth $8.6 million to Series B purchasers and convertible notes holders.
Celsis International, the global leader in rapid microbial detection, announced it has recently updated its Drug Master Files with the U.S. Food & Drug Administration (FDA) to include information on testing both non-sterile and sterile raw materials, in-process solutions and finished goods on the Celsis system.
Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced the U.S. Food and Drug Administration (FDA) has agreed to the Company's updated product specifications for SURFAXIN® (lucinactant) Intratracheal Suspension which was approved for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk for RDS.
The Wilson Medical Center Board of Directors has taken the next step in becoming part of Duke LifePoint Healthcare. The organizations have signed a definitive agreement to form a joint venture. The proposed joint venture, which will provide Wilson Medical Center with resources to enhance its services and invest in its growth, is moving forward following a positive vote by the Wilson County Board of Commissioners. The agreement is under review by the Attorney General of North Carolina.
For years, pharmaceutical companies have sought to restrict public access to drug safety data collected in clinical trials on the basis that it is proprietary information, arguing that competitors could use that information in the development of their own products.
› Verified 1 days ago
Dr. Ahmed Abdel Mekkawy, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 925 Clifton Ave, Suite 101, Clifton, NJ 07013 Phone: 973-778-5070 Fax: 973-778-2878 | |
Dr. Pearl Korenblit, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 1011 Clifton Ave, First Floor, Clifton, NJ 07013 Phone: 973-928-5490 Fax: 973-928-5493 | |
Louise Ashley Albornoz, MD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 1011 Clifton Ave, Clifton, NJ 07013 Phone: 973-778-6611 Fax: 973-473-8434 | |
Dr. Fadwa Sumrein, D.O Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2 Brighton Rd Ste 400, Clifton, NJ 07012 Phone: 862-297-9696 Fax: 862-297-9695 | |
Joanna Crincoli, DO Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 10 Frances St Fl 2, Clifton, NJ 07014 Phone: 973-902-4449 | |
Dr. Ravinder M Narang, M.D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 721 Clifton Ave, Clifton, NJ 07013 Phone: 973-471-9454 | |
Kedar Sankholkar, MD, MS Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1030 Clifton Ave, Clifton, NJ 07013 Phone: 973-778-3777 Fax: 973-778-3252 |